# Human Rating Form — GDgpt Clinical Utility Evaluation

> **Instructions**: Rate each question on D1-D5 (1=Poor, 3=Adequate, 5=Excellent).
> Fill in the table below. Use same rubric as the LLM judge.
> Return this file after completion.

## Rubric Summary
- **D1 Factual Accuracy**: Are gene/pathway/drug claims correct?
- **D2 Completeness**: Are key evidence items covered?
- **D3 Traceability**: Are claims attributed to specific sources/edges?
- **D4 Clinical Safety**: Does it acknowledge uncertainty vs. fabricate?
- **D5 Coherence**: Is it logically structured and readable?

---
## Question 1: `ind_dc_87845f398756`
**Q**: What genes and pathways are associated with breast neoplasm? What are the key mechanisms?

### System A (GDgpt)
```
The mechanism for breast neoplasm involves hormone-driven cell proliferation and survival (e.g., Estrogen-dependent signaling via ESR1, BCL2), oncogenic signaling through PI3K/AKT and RAF/MAPK pathways (e.g., ERBB2, AKT1, FGFR2 involvement), drug resistance via ABC transporter genes (e.g., ABCB1-mediated efflux), and tumor microenvironment modulation through immune and inflammatory pathways (e.g., Interleukin signaling, Neutrophil degranulation).
```
```

### System B (GPT-4o)
```
Breast neoplasms are associated with several key genes and pathways that drive tumorigenesis, progression, and therapeutic resistance. Below is a concise outline of the most relevant genes, pathways, and mechanisms:

### **Genes Frequently Associated with Breast Neoplasm:**
1. **Tumor Suppressor Genes:**
   - **TP53**: Regulates cell cycle arrest, apoptosis, and DNA repair. Mutations are common in triple-negative breast cancer (TNBC).
   - **BRCA1/BRCA2**: Critical for homologous recombination (HR) DNA repair. Germline mutations increase the risk for hereditary breast and ovarian cancer syndromes.
   - **PTEN**: Regulates PI3K/AKT signaling and cell survival. Loss of PTEN is associated with aggressive phenotypes.

2. **Oncogenes:**
   - **PIK3CA**: Activates the PI3K/AKT/mTOR pathway, prom
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 2: `ind_dc_efd557a940d1`
**Q**: What genes and pathways are associated with undifferentiated carcinoma of the corpus uteri? What are the key mechanisms?

### System A (GDgpt)
```
{
  "Consistency": {
    "Disease_Gene_Associations": [
      {"gene": "ABCA3", "disease": "undifferentiated carcinoma of the corpus uteri", "sources": ["NCBI", "MONDO"]},
      {"gene": "ABCA4", "disease": "undifferentiated carcinoma of the corpus uteri", "sources": ["NCBI", "MONDO"]},
      {"gene": "ABCB1", "disease": "undifferentiated carcinoma of the corpus uteri", "sources": ["NCBI", "MONDO"]},
      {"gene": "ABCB10", "disease": "undifferentiated carcinoma of the corpus uteri", "sources": ["NCBI", "MONDO"]}
    ],
    "Disease_Gene_Pathway_Bridges": [
      {"pathway": "Interleukin-4 and Interleukin-13 signaling", "genes": ["NOS2", "PTGS2", "HMOX1", "MAOA", "MMP9"], "sources": ["REACTOME", "MONDO", "NCBI"]},
      {"pathway": "Estrogen-dependent gene expression", "genes": ["ESR1", "
```

### System B (GPT-4o)
```
Undifferentiated carcinoma of the corpus uteri is a rare and aggressive subtype of endometrial cancer characterized by high-grade histology and loss of differentiation. Its molecular mechanisms are not fully understood, but studies have identified several key genes and pathways associated with its pathogenesis:

### **Key Genes:**
1. **SWI/SNF Complex Genes**:
   - **SMARCA4**: Loss-of-function mutations in SMARCA4 (BRG1) are implicated in undifferentiated carcinoma, leading to defects in chromatin remodeling.
   - **ARID1A**: Mutations in ARID1A, another component of the SWI/SNF chromatin remodeling complex, are frequently seen in aggressive endometrial carcinomas.

2. **TP53**:
   - Mutations in TP53 are common in undifferentiated and high-grade endometrial carcinomas, leading to loss of
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 3: `ind_dc_182a1e726ac1`
**Q**: What genes and pathways are associated with schizophrenia? What are the key mechanisms?

### System A (GDgpt)
```
Schizophrenia involves genetic variants (e.g., GRIN1, ABCA13, ABCB1) disrupting synaptic signaling (RAF/MAP kinase cascade, GPCR signaling), lipid transport (ABCA genes), and neuroimmune pathways (Neutrophil degranulation, Interleukin signaling), contributing to neuronal plasticity, neurotransmitter imbalances, and neuroinflammation.
```
```

### System B (GPT-4o)
```
Schizophrenia is a complex neuropsychiatric disorder with both genetic and environmental contributors. While no single gene is solely responsible, several genes and pathways have been implicated in its pathogenesis. Below is a concise summary of key genes, pathways, and mechanisms:

### Key Genes:
1. **COMT (Catechol-O-Methyltransferase):** Involved in dopamine metabolism; polymorphisms (e.g., Val158Met) may affect dopamine signaling in the prefrontal cortex.
2. **DISC1 (Disrupted in Schizophrenia 1):** Plays a role in neuronal development, synaptic signaling, and brain connectivity.
3. **NRG1 (Neuregulin 1):** Involved in synaptic plasticity and myelination.
4. **DRD2 (Dopamine D2 Receptor):** A key target of antipsychotic medications; altered dopamine receptor signaling is central to sch
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 4: `ind_dc_9c33ed784d74`
**Q**: What genes and pathways are associated with colorectal cancer? What are the key mechanisms?

### System A (GDgpt)
```
A2M facilitates tumor invasion and metastasis in colorectal cancer by enabling extracellular matrix remodeling through the "Degradation of the extracellular matrix" pathway.
```

### System B (GPT-4o)
```
Colorectal cancer (CRC) is associated with a complex interplay of genetic alterations and dysregulated signaling pathways. Key genes and pathways involved include:

### 1. **APC/β-Catenin (Wnt Signaling Pathway):**
   - **Genes:** APC (tumor suppressor), CTNNB1 (encodes β-catenin).
   - **Mechanism:** Loss-of-function mutations in APC lead to aberrant activation of Wnt signaling, allowing β-catenin to accumulate and translocate to the nucleus, where it drives transcription of oncogenic target genes like MYC and CCND1.

### 2. **TP53 (Tumor Suppressor Pathway):**
   - **Gene:** TP53.
   - **Mechanism:** Mutations in TP53 disrupt cell cycle arrest, apoptosis, and DNA repair, promoting genomic instability and tumor progression.

### 3. **KRAS/NRAS and MAPK Pathway:**
   - **Genes:** KRAS, NRA
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 5: `ind_dc_6847df815fd5`
**Q**: What genes and pathways are associated with familial prostate carcinoma? What are the key mechanisms?

### System A (GDgpt)
```
Oncogenic signaling drives tumorigenesis (PI3K/AKT, RAF/MAP), inflammatory pathways remodel the tumor microenvironment, and DNA repair deficiencies (BRCA2) contribute to hereditary risk in familial prostate carcinoma.
```
```

### System B (GPT-4o)
```
Familial prostate carcinoma is associated with several genes and pathways that influence hereditary predisposition and tumorigenesis. Key genes and mechanisms include:

### **Genes and Pathways**
1. **DNA Damage Repair Pathways**
   - **BRCA1/BRCA2**: Mutations in these genes, primarily known for their role in breast and ovarian cancers, are also implicated in prostate cancer, especially aggressive forms. They impair homologous recombination repair of DNA damage, leading to genomic instability.
   - **ATM**: A gene involved in DNA damage response. Loss-of-function mutations in ATM can lead to defective repair mechanisms and increased cancer risk.
   - **CHEK2**: Encodes a checkpoint kinase involved in DNA repair. Mutations in CHEK2 are linked to familial prostate cancer due to impaired cel
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 6: `ind_dc_3bb0a1cdbe69`
**Q**: What genes and pathways are associated with hepatocellular carcinoma? What are the key mechanisms?

### System A (GDgpt)
```
Hepatocellular carcinoma involves genes such as A2M, AADAT, ABCB1, and ABCB4, which are linked to pathways including Neutrophil degranulation, Resolution/Separation of Sister Chromatids, Interleukin-4/13 signaling, and RHO GTPases Activate Formins. These mechanisms highlight immune dysregulation, chronic inflammation, genomic instability, and cytoskeletal remodeling as contributors to cancer progression.
```
```

### System B (GPT-4o)
```
Hepatocellular carcinoma (HCC) is associated with several genetic alterations and pathways that drive tumor development and progression. Below is a summary of key genes, pathways, and mechanisms involved:

### 1. **Key Genes Associated with HCC**
   - **TP53**: Frequently inactivated in HCC, leading to loss of cell cycle regulation and genomic instability.
   - **CTNNB1 (β-catenin)**: Activating mutations result in constitutive activation of the Wnt/β-catenin signaling pathway, promoting cell proliferation and survival.
   - **TERT (telomerase reverse transcriptase)**: Promoter mutations upregulate telomerase activity, leading to immortalization of cancer cells.
   - **AXIN1**: Mutations in this negative regulator of Wnt signaling enhance β-catenin activity.
   - **ARID1A/ARID2**: Loss-of-
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 7: `ind_dc_d130a7eb1f15`
**Q**: What genes and pathways are associated with adenocarcinoma of liver and intrahepatic biliary tract? What are the key mechanisms?

### System A (GDgpt)
```
Adenocarcinoma of the liver and intrahepatic biliary tract involves key genes (A2M, ABCB1, CDK1, AURKB) and pathways (e.g., Resolution and Separation of Sister Chromatids, RHO GTPases Activate Formins, Neutrophil Degranulation). These mechanisms collectively drive tumor growth, invasion, immune evasion, and genomic instability through chromatid cohesion disruption, cytoskeletal remodeling, and inflammatory processes.
```
```

### System B (GPT-4o)
```
Adenocarcinoma of the liver and intrahepatic biliary tract (encompassing hepatocellular carcinoma [HCC] and intrahepatic cholangiocarcinoma [iCCA]) involves several genes and pathways that drive tumorigenesis. Below is a concise overview:

### 1. **Hepatocellular Carcinoma (HCC)**
   - **Key Genes**:
     - **TP53**: Frequently mutated, leading to loss of tumor suppressor function.
     - **CTNNB1 (β-catenin)**: Mutations drive Wnt/β-catenin pathway activation.
     - **TERT**: Promoter mutations result in telomerase activation and genomic stability.
     - **AXIN1**: Mutations impair Wnt pathway regulation.
     - **ARID1A/ARID2**: Chromatin remodeling gene mutations contribute to epigenetic dysregulation.
   
   - **Key Pathways**:
     - **Wnt/β-catenin pathway**: Aberrant activation pr
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 8: `ind_dc_8df2021cf75b`
**Q**: What genes and pathways are associated with undifferentiated carcinoma of liver and intrahepatic biliary tract? What are the key mechanisms?

### System A (GDgpt)
```
Chromosomal instability (via chromatid cohesion and spindle checkpoint pathways), cytoskeletal remodeling (via RHO GTPases Activate Formins), and tumor-associated inflammation (via Neutrophil degranulation) drive the pathogenesis of undifferentiated carcinoma of the liver and intrahepatic biliary tract.
```
```

### System B (GPT-4o)
```
Undifferentiated carcinoma of the liver and intrahepatic biliary tract is rare, and its molecular underpinnings are not fully characterized. However, based on available data, key genes and pathways potentially associated with this tumor type include:

### Associated Genes:
1. **TP53**: Frequently mutated in poorly differentiated or aggressive liver and biliary tract cancers, leading to impaired DNA damage response and cell cycle regulation.
2. **KRAS**: Activating mutations in KRAS are common in intrahepatic cholangiocarcinoma, driving growth and proliferation through MAPK/ERK signaling.
3. **IDH1/IDH2**: Mutations in these genes are seen in cholangiocarcinoma, resulting in abnormal 2-hydroxyglutarate production and epigenetic dysregulation.
4. **FGFR2**: Fusions in FGFR2 are specifically 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 9: `ind_dc_f30ad13c7079`
**Q**: What genes and pathways are associated with squamous cell carcinoma of liver and intrahepatic biliary tract? What are the key mechanisms?

### System A (GDgpt)
```
Squamous cell carcinoma of the liver is driven by genomic instability from mitotic dysregulation (via CDK1, AURKB, BIRC5, PLK1, CENPE, KIF2C). Cytoskeletal remodeling (RHO GTPases Activate Formins pathway) contributes to tumor migration and metastasis. Inflammation and immune evasion are mediated by Neutrophil degranulation pathway (e.g., SERPINA1, GSTP1). A2M contributes to extracellular matrix degradation and tumor microenvironment remodeling, while ABCB1 and ABCB4 may promote chemoresistance and bile acid transport.
```

### System B (GPT-4o)
```
Squamous cell carcinoma (SCC) of the liver and intrahepatic biliary tract is an extremely rare malignancy, and its molecular mechanisms are not well characterized. However, based on existing knowledge from biliary tract cancers and SCCs in other sites, several genes and pathways may be implicated:

### Key Genes and Pathways:
1. **TP53**: Mutations in TP53 are frequently observed in biliary tract cancers and SCCs, leading to loss of cell cycle regulation and genomic instability.

2. **KRAS**: Mutations in KRAS are common in biliary tract cancers and may play a role in SCC transformation by activating the MAPK/ERK signaling pathway.

3. **PIK3CA/AKT/mTOR Pathway**: Dysregulation of this pathway, through PIK3CA mutations or PTEN loss, is implicated in various SCCs and biliary tract malignanc
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |
